Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.

Today, we return to Filament Health (FH.NEO), a Canadian psychedelics company developing novel drug delivery protocols for naturally extracted proprietary psilocybin compounds in the pharmaceutical grade treatment of neurological conditions such as depression and anxiety.

Enjoy!